Royalty Pharma PLC (RPRX) FinancialsRPRXFinancialRoyalty Pharma PLC

Evaluating the bottom line, Royalty Pharma PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.75%, while the net margin is 12.09%. These profitability ratios, combined with a Return on Equity (ROE) of 12.37%, provide a clear picture of how effectively RPRX converts its operational activities into shareholder value.

In the context of the broader market, RPRX competes directly with industry leaders such as HLN and BIIB. With a market capitalization of $34.99B, it holds a significant position in the sector. When comparing efficiency, RPRX's gross margin of 100.00% stands against HLN's 66.10% and BIIB's 65.46%. Such benchmarking helps identify whether Royalty Pharma PLC is trading at a premium or discount relative to its financial performance.

Royalty Pharma has shown consistent revenue growth, with total revenue increasing to $674.14 million in Q2 2026, a 14% increase from the previous quarter. The company also returned approximately $370 million to shareholders in the first half of 2026, reflecting strong cash flow.